This phase I study is assessing how safe, tolerable and effective a targeted therapy (VAY736) is alone, and in combination with cancer drug lenalidomide, in people with relapsed or refractory B-cell non-Hodgkin lymphoma.
This trial is treating patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)
This trial is comprised of two cohorts that both have a dose escalation part and a dose expansion part. In Cohort 1, participants will receive VAY736 as a single agent. In Cohort 2, participants will receive VAY736 in combination with lenalidomide.
Recruiting Hospitals Read More